NCT07100080 2026-04-16
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
Bristol-Myers Squibb
BioNTech SE
Hoffmann-La Roche
AbbVie
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
Eikon Therapeutics
Regeneron Pharmaceuticals
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Transgene
National Cancer Institute (NCI)
Hamamatsu University